CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma

Trial ID or NCT#

NCT04727242

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to find out if giving a dose of heated chemotherapy in the abdomen immediately after surgery that is done to remove uterine leiomyosarcoma type of cancer will help lower the risk of the cancer coming back in the future.

Official Title

Phase 2 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Gemcitabine Followed by Systemic Adjuvant Chemotherapy With Dacarbazine for Locally Recurrent Uterine Leiomyosarcoma (LMS)

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. 1. Histologically confirmed diagnosis of uterine leiomyosarcoma (LMS) with evidence of local recurrence. 2. Imaging provides evidence of locally recurrent uterine LMS. 3. Candidate for potentially radical, maximal effort cytoreductive surgery at the discretion and expertise of the treating physician. 4. Age ≥ 18 years. 5. Life expectancy > 3 months. 6. Women of childbearing potential (WOCBP) will have a negative pregnancy test ≤ 7 days prior to surgery (this test can be omitted if subject is post menopausal by either surgery or elevated FSH) 7. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2. 8. Hemoglobin (HGB) ≥ 9 g/dL. 9. White blood cell count (WBC) ≥ 3.0 K/ul. 10. Absolute neutrophil count (ANC) ≥ 1.5 K/ul. 11. Platelets (PLT) ≥ 100 K/ul. 12. Total bilirubin within normal institutional limits. 13. Serum glutamic oxaloacetic transaminase (SGOT/Serum glutamic pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN). 14. Creatinine < 1.5 x ULN or creatinine clearance > 60 mL/min according to Cockroft Gault formula. 15. Prothrombin Time (PT) such that international normalized ratio (INR) is < 1.5 (or an in range INR, usually between 2 and 3, if a subject is on a stable dose of therapeutic warfarin or low molecular weight heparin) and a partial thromboplastin time (PTT) < 1.2 times control. 16. Serum albumin ≥ 2.5 g/dL. 17. Ability to understand and the willingness to personally sign the written IRB approved informed consent document. Note that this study does not allow the use of a legally authorized representative
Exclusion Criteria:
  1. 1. Recurrence of LMS within less than 6 months after the last dose of gemcitabine. 2. Active extra abdominal disease including active malignant pleural effusion. Subjects who have been successfully treated with neoadjuvant chemotherapy and no longer have (malignant) pleural effusions may be included. 3. Prior gemcitabine given in non adjuvant setting. 4. Prior treatment with dacarbazine. 5. Active infection requiring antibiotics. 6. Unresolved toxic effects of prior therapy (except alopecia). Resolution is considered ≤ Grade 1 per NCI CTCAE, version 5.0. 7. Pregnant. 8. Breast feeding. 9. Presence of metastatic liver disease
View All Criteria
Show Less

Investigator(s)

Kristen N Ganjoo
Kristen N Ganjoo
Sarcoma specialist, Medical oncologist
Professor of Medicine (Oncology)
Byrne Lee, MD FACS
Byrne Lee, MD FACS
Surgical oncologist, General surgeon
Clinical Professor, Surgery - General Surgery

Contact us to find out if this trial is right for you.

Contact

Ghazal Jawed
gjawed@stanford.edu

View on ClinicalTrials.gov